SPORE guidelines mandate diligent efforts to identify and fund pilot projects to explore innovative ideas that may eventually reduce the incidence and morbidity or increase the survival of lung cancer. Both UTSW and UTMDACC have significant records in obtaining and administering development funds via the SPORE and outside funds and have found the SPORE Developmental Research Program to be one of the most valuable and productive of the SPORE components. UTSW has a -25-year track record of administering developmental funds for cancer research. These funds are available through the American Cancer Society (ACS) Institutional Grant IN-142. The ACS funds must be distributed to new investigators in cancer research whose proposed pilot projects are especially worthy and likely to gain national grant support through the peer-review mechanism. At UTMDACC, more than $1,000,000 in development funds is made available yearly from clinical revenues to both clinical and basic science faculty for development projects. In addition, the UTMDACC Co-Pi (Jack Roth) has administered a developmental research program in innovative cancer therapies funded by the W. M. Keck Foundation using an external peer-review mechanism. This additional funding underscores UTMDACC's commitment to translational research and provides additional support for development projects. As part of the UTSW and UTMDACC renewed commitment to the SPORE, an additional $150,000 from Texas Tobacco Settlement Funds and other institutional funds will be made available from UTSW ($50,000) and UTMDACC ($100,000) for Lung Cancer SPORE Developmental Research Projects. The development of innovative research ideas in lung cancer is critically dependent on the availability of flexible funding for pilot projects. The purpose of the SPORE Developmental Research Program is to encourage and develop laboratory research projects that will result in clinically testable hypotheses with potential for reducing lung cancer incidence or morbidity or for increasing survival. Both laboratory and clinical research projects are eligible for funding, provided they are translational in nature. A proportion of the SPORE NCI budget ($100,000 in direct costs, $50,000 to Developmental Projects and $50,000 to Career Development Projects - see Career Development Section) will be allocated yearly to support pilot projects at both UTSW and UTMDACC. These allocations fulfill the SPORE Guideline requirements for budgeting. However, we stress, this will be combined with a yearly UTSW and MDACC institutional commitment of $150,000 (UTSW $50,000 and MD Anderson Cancer Center $100,000) which represent $150,000 for Developmental Projects plues $50,000 from the SPORE.. Thus, the combined UTSW + MDACC total from NCI and Institutional funds for Lung Cancer SPORE Developmental Projects is $200,000. Such funding will be limited to a maximum of $50,000 per year per project, however, most of the awards are for ~$25,000 per project for a total of ~8 Developmental Projects awarded per year. Funding will be for one year and will be renewable for one additional year. While the budget divides the $100,000 in direct costs equally between the two institutions, the SPORE Developmental Program will allocate funding based on merit using the review process described in a later section. These projects may, and often involve collaborations between UTSW and UTMDACC investigators particularly given the use of SPORE resources such as the SPORE Pathology Core B, Biostatistics Core C, and Bioinformatics Core D, which greatly augment the translational capability of the Developmental Awards. These projects may also be awarded to investigators at other institutions. For example Dr. Andrew Ellington on the faculty of UT Austin received a Development award for deriving RNA aptamers specific for lung cancer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA070907-15
Application #
8375373
Study Section
Special Emphasis Panel (ZCA1-GRB-I)
Project Start
Project End
2014-04-30
Budget Start
2012-05-01
Budget End
2013-04-30
Support Year
15
Fiscal Year
2012
Total Cost
$71,378
Indirect Cost
$12,216
Name
University of Texas Sw Medical Center Dallas
Department
Type
DUNS #
800771545
City
Dallas
State
TX
Country
United States
Zip Code
75390
Ma, Junsheng; Hobbs, Brian P; Stingo, Francesco C (2018) Integrating genomic signatures for treatment selection with Bayesian predictive failure time models. Stat Methods Med Res 27:2093-2113
Yi, Faliu; Yang, Lin; Wang, Shidan et al. (2018) Microvessel prediction in H&E Stained Pathology Images using fully convolutional neural networks. BMC Bioinformatics 19:64
Song, Kai; Bi, Jia-Hao; Qiu, Zhe-Wei et al. (2018) A quantitative method for assessing smoke associated molecular damage in lung cancers. Transl Lung Cancer Res 7:439-449
Ji, Xuemei; Bossé, Yohan; Landi, Maria Teresa et al. (2018) Identification of susceptibility pathways for the role of chromosome 15q25.1 in modifying lung cancer risk. Nat Commun 9:3221
He, Min; Liu, Shanshan; Gallolu Kankanamalage, Sachith et al. (2018) The Epithelial Sodium Channel (?ENaC) Is a Downstream Therapeutic Target of ASCL1 in Pulmonary Neuroendocrine Tumors. Transl Oncol 11:292-299
Parra, Edwin R; Villalobos, Pamela; Behrens, Carmen et al. (2018) Effect of neoadjuvant chemotherapy on the immune microenvironment in non-small cell lung carcinomas as determined by multiplex immunofluorescence and image analysis approaches. J Immunother Cancer 6:48
Guo, Hou-Fu; Tsai, Chi-Lin; Terajima, Masahiko et al. (2018) Pro-metastatic collagen lysyl hydroxylase dimer assemblies stabilized by Fe2+-binding. Nat Commun 9:512
Meraz, Ismail M; Majidi, Mourad; Cao, Xiaobo et al. (2018) TUSC2 Immunogene Therapy Synergizes with Anti-PD-1 through Enhanced Proliferation and Infiltration of Natural Killer Cells in Syngeneic Kras-Mutant Mouse Lung Cancer Models. Cancer Immunol Res 6:163-177
Zhang, Liren; Lin, Jing; Ye, Yuanqing et al. (2018) Serum MicroRNA-150 Predicts Prognosis for Early-Stage Non-Small Cell Lung Cancer and Promotes Tumor Cell Proliferation by Targeting Tumor Suppressor Gene SRCIN1. Clin Pharmacol Ther 103:1061-1073
Bayo, Juan; Tran, Tram Anh; Wang, Lei et al. (2018) Jumonji Inhibitors Overcome Radioresistance in Cancer through Changes in H3K4 Methylation at Double-Strand Breaks. Cell Rep 25:1040-1050.e5

Showing the most recent 10 out of 1059 publications